Limits...
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.

Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, Zack DJ, Fiorentino D - Ann. Rheum. Dis. (2012)

Bottom Line: Baseline comparisons with age and gender-matched norms and treatment-associated changes in domain scores were quantified using spydergrams and the health utility SF-6D measure.Treatment with etanercept resulted in improvements in PCS and MCS scores as well as individual SF-36 domains across all indications.Treatment with etanercept was associated with improvements in PCS and MCS scores as well as individual domain scores in patients with RA, PsA and psoriasis.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunology/Rheumatology, Stanford University, 306 Ramona Road, Portola Valley, CA 94028, USA. vstrand@stanford.edu

ABSTRACT

Objectives: To compare health-related quality of life (HRQoL) before and after treatment with etanercept in patients with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA) and psoriasis using spydergram representations.

Methods: Data from randomised, controlled trials of etanercept in patients with RA, PsA and psoriasis were analysed. HRQoL was assessed by the medical outcomes survey short form 36 (SF-36) physical (PCS) and mental (MCS) component summary and domain scores. Baseline comparisons with age and gender-matched norms and treatment-associated changes in domain scores were quantified using spydergrams and the health utility SF-6D measure.

Results: Mean baseline PCS scores were lower than age and gender-matched norms in patients with RA and PsA, but near normative values in patients with psoriasis; MCS scores at baseline were near normal in PsA and psoriasis but low in RA. Treatment with etanercept resulted in improvements in PCS and MCS scores as well as individual SF-36 domains across all indications. Mean baseline SF-6D scores were higher in psoriasis than in RA or PsA; clinically meaningful improvements in SF-6D were observed in all three patient populations following treatment with etanercept.

Conclusions: Patients with RA, PsA and psoriasis demonstrated unique HRQoL profiles at baseline. Treatment with etanercept was associated with improvements in PCS and MCS scores as well as individual domain scores in patients with RA, PsA and psoriasis.

Show MeSH

Related in: MedlinePlus

Short form 36 (SF-36) spydergrams for patients with rheumatoid arthritis. Mean SF-36 scores at baseline and week 52 and age and gender-matched norms are shown for patients receiving (A) methotrexate or (B) etanercept plus methotrexate. (C) Mean SF-36 scores at baseline and week 52 for patients treated with methotrexate or etanercept plus methotrexate are compared. Mean SF-36 scores for age and gender-matched norms are also shown. BP, bodily pain; ETN, etanercept; GH, general health; MH, mental health; MTX, methotrexate; PF, physical function; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3375587&req=5

Figure 1: Short form 36 (SF-36) spydergrams for patients with rheumatoid arthritis. Mean SF-36 scores at baseline and week 52 and age and gender-matched norms are shown for patients receiving (A) methotrexate or (B) etanercept plus methotrexate. (C) Mean SF-36 scores at baseline and week 52 for patients treated with methotrexate or etanercept plus methotrexate are compared. Mean SF-36 scores for age and gender-matched norms are also shown. BP, bodily pain; ETN, etanercept; GH, general health; MH, mental health; MTX, methotrexate; PF, physical function; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.

Mentions: Large reductions in domain scores were reported by RA patients at baseline and were largest in RP and BP (figure 1A,B). After 52 weeks of treatment, statistically significant (p<0.0001) and clinically meaningful improvements (≥MCID) across all domains were evident with both treatments. Greatest improvements were seen in both treatment groups in domains with the lowest scores at baseline: RP (improvements of 46.5 vs 40.8 points in the etanercept plus methotrexate vs methotrexate arms), BP (37.2 vs 29.6 points) and RE (32.7 vs 25.9 points). Etanercept plus methotrexate therapy was associated with greater improvements in PF, BP and VT domains compared with methotrexate therapy alone (figure 1C).


Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.

Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, Zack DJ, Fiorentino D - Ann. Rheum. Dis. (2012)

Short form 36 (SF-36) spydergrams for patients with rheumatoid arthritis. Mean SF-36 scores at baseline and week 52 and age and gender-matched norms are shown for patients receiving (A) methotrexate or (B) etanercept plus methotrexate. (C) Mean SF-36 scores at baseline and week 52 for patients treated with methotrexate or etanercept plus methotrexate are compared. Mean SF-36 scores for age and gender-matched norms are also shown. BP, bodily pain; ETN, etanercept; GH, general health; MH, mental health; MTX, methotrexate; PF, physical function; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3375587&req=5

Figure 1: Short form 36 (SF-36) spydergrams for patients with rheumatoid arthritis. Mean SF-36 scores at baseline and week 52 and age and gender-matched norms are shown for patients receiving (A) methotrexate or (B) etanercept plus methotrexate. (C) Mean SF-36 scores at baseline and week 52 for patients treated with methotrexate or etanercept plus methotrexate are compared. Mean SF-36 scores for age and gender-matched norms are also shown. BP, bodily pain; ETN, etanercept; GH, general health; MH, mental health; MTX, methotrexate; PF, physical function; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.
Mentions: Large reductions in domain scores were reported by RA patients at baseline and were largest in RP and BP (figure 1A,B). After 52 weeks of treatment, statistically significant (p<0.0001) and clinically meaningful improvements (≥MCID) across all domains were evident with both treatments. Greatest improvements were seen in both treatment groups in domains with the lowest scores at baseline: RP (improvements of 46.5 vs 40.8 points in the etanercept plus methotrexate vs methotrexate arms), BP (37.2 vs 29.6 points) and RE (32.7 vs 25.9 points). Etanercept plus methotrexate therapy was associated with greater improvements in PF, BP and VT domains compared with methotrexate therapy alone (figure 1C).

Bottom Line: Baseline comparisons with age and gender-matched norms and treatment-associated changes in domain scores were quantified using spydergrams and the health utility SF-6D measure.Treatment with etanercept resulted in improvements in PCS and MCS scores as well as individual SF-36 domains across all indications.Treatment with etanercept was associated with improvements in PCS and MCS scores as well as individual domain scores in patients with RA, PsA and psoriasis.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunology/Rheumatology, Stanford University, 306 Ramona Road, Portola Valley, CA 94028, USA. vstrand@stanford.edu

ABSTRACT

Objectives: To compare health-related quality of life (HRQoL) before and after treatment with etanercept in patients with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA) and psoriasis using spydergram representations.

Methods: Data from randomised, controlled trials of etanercept in patients with RA, PsA and psoriasis were analysed. HRQoL was assessed by the medical outcomes survey short form 36 (SF-36) physical (PCS) and mental (MCS) component summary and domain scores. Baseline comparisons with age and gender-matched norms and treatment-associated changes in domain scores were quantified using spydergrams and the health utility SF-6D measure.

Results: Mean baseline PCS scores were lower than age and gender-matched norms in patients with RA and PsA, but near normative values in patients with psoriasis; MCS scores at baseline were near normal in PsA and psoriasis but low in RA. Treatment with etanercept resulted in improvements in PCS and MCS scores as well as individual SF-36 domains across all indications. Mean baseline SF-6D scores were higher in psoriasis than in RA or PsA; clinically meaningful improvements in SF-6D were observed in all three patient populations following treatment with etanercept.

Conclusions: Patients with RA, PsA and psoriasis demonstrated unique HRQoL profiles at baseline. Treatment with etanercept was associated with improvements in PCS and MCS scores as well as individual domain scores in patients with RA, PsA and psoriasis.

Show MeSH
Related in: MedlinePlus